0 Bewertungen0% fanden dieses Dokument nützlich (0 Abstimmungen)
22 Ansichten1 Seite
Clinical failure is defined as a new or recurrent clinical event indicating severe immunodeficiency after 6 months of effective ART. Immunological failure is defined as a CD4 count falling to or below the baseline level, or persistent CD4 levels below 100 cells/mm3. Virological failure is defined as a plasma viral load above 1000 copies/ml based on two consecutive measurements after 3 months of ART and adherence support.
Clinical failure is defined as a new or recurrent clinical event indicating severe immunodeficiency after 6 months of effective ART. Immunological failure is defined as a CD4 count falling to or below the baseline level, or persistent CD4 levels below 100 cells/mm3. Virological failure is defined as a plasma viral load above 1000 copies/ml based on two consecutive measurements after 3 months of ART and adherence support.
Clinical failure is defined as a new or recurrent clinical event indicating severe immunodeficiency after 6 months of effective ART. Immunological failure is defined as a CD4 count falling to or below the baseline level, or persistent CD4 levels below 100 cells/mm3. Virological failure is defined as a plasma viral load above 1000 copies/ml based on two consecutive measurements after 3 months of ART and adherence support.
15 WHO definitions of clinical, immunological and virological
failure for the decision to switch ART regimens
Failure Definition Comments
Adults and adolescents
The condition must be New or recurrent clinical event indicating differentiated from immune severe immunodeficiency (WHO clinical reconstitution inflammatory stage 4 condition) a after 6 months of syndrome b occurring after effective treatment initiating ART Clinical failure Children For adults, certain WHO clinical New or recurrent clinical event indicating stage 3 conditions (pulmonary TB advanced or severe immunodefiency and severe bacterial infections) (WHO clinical stage 3 and 4 clinical may also indicate treatment condition with exception of TB) after 6 failure a months of effective treatment
Without concomitant or recent
Adults and adolescents infection to cause a transient CD4 count falls to the baseline (or decline in the CD4 cell count below) A systematic review found or that current WHO clinical and immunological criteria have low Persistent CD4 levels below sensitivity and positive predictive 100 cells/mm3 value for identifying individuals Immunological failure with virological failure (182) . The Children predicted value would be expected to be even lower with earlier ART Younger than 5 years initiation and treatment failure at Persistent CD4 levels below 200 cells/mm3 higher CD4 cell counts. There is or <10% currently no proposed alternative definition of treatment failure and Older than 5 years no validated alternative definition Persistent CD4 levels below 100 cells/mm3 of immunological failure
The optimal threshold for defining
virological failure and the need for switching ART regimen has not been determined Plasma viral load above 1000 copies/ An individual must be taking ART Virological ml based on two consecutive viral load for at least 6 months before it can failure measurements after 3 months, with be determined that a regimen has adherence support failed Assessment of viral load using DBS and point-of-care technologies should use a higher threshold
a See the list of clinical conditions associated with advanced or severe HIV disease associated with immunodeficiency in Annex 1. b Section 6.1 discusses immune reconstitution inflammatory syndrome.